Head-To-Head Contrast: TransCode Therapeutics (NASDAQ:RNAZ) vs. Century Therapeutics (NASDAQ:IPSC)

TransCode Therapeutics (NASDAQ:RNAZ) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Volatility & Risk

TransCode Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for TransCode Therapeutics and Century Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1	0	1	0	2.00
Century Therapeutics	1	0	4	0	2.60

TransCode Therapeutics currently has a consensus price target of $280.00, suggesting a potential upside of 1,878.80%. Century Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 559.40%. Given TransCode Therapeutics’ higher possible upside, research analysts plainly believe TransCode Therapeutics is more favorable than Century Therapeutics.

Earnings & Valuation

This table compares TransCode Therapeutics and Century Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$16.75 million	N/A	N/A
Century Therapeutics	$6.59 million	7.46	-$126.57 million	($0.29)	-1.96

TransCode Therapeutics has higher earnings, but lower revenue than Century Therapeutics.

Institutional and Insider Ownership

50.2% of Century Therapeutics shares are held by institutional investors. 0.0% of TransCode Therapeutics shares are held by company insiders. Comparatively, 5.0% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares TransCode Therapeutics and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-378.30%	-186.01%
Century Therapeutics	-19.10%	-11.53%	-6.94%

Summary

Century Therapeutics beats TransCode Therapeutics on 8 of the 11 factors compared between the two stocks.

About TransCode Therapeutics

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.